Sucraid® (Sacrosidase)

Sucraid® is the first and only pharmacologic therapy approved by the FDA as a simple, safe and effective enzyme replacement therapy of the genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase disease.

To learn more about Sucraid®, to review the prescribing information, learn about diagnostic procedures, or read a primer on congenital and acquired sucrase deficiencies, please visit Sucraid.net or call 1-866-740-2743 (CSID).

"I HAVE BEEN TOLD SUCRAID IS DISCONTINUED. HELP!"
First, rest assured, Sucraid® has not been discontinued. Such incorrect information comes about due to changes in the distribution system for Sucraid®. This is important information if you are currently taking Sucraid® (sacrosidase) oral Solution or are a caregiver for a Sucraid® patient in the USA.

In recent years the major distribution wholesalers in the USA have become more reluctant to stock rare-disease products such as Sucraid®. In the last few months we have received many calls from existing Sucraid® patients or their caregivers having difficulty obtaining their essential medication. In some cases, false information about Sucraid® being discontinued has been given to the patient or caregiver.

To resolve this problem:

QOL Medical, makers of Sucraid®, are switching to an exclusive distribution arrangement with a company that will ship the medicine free-of-charge directly to the patient’s home. This arrangement will guarantee all patients receive the medicine in time and when needed without having the stress of finding retail pharmacies that can fulfill their prescription. Additionally, the same exclusive distribution arrangement will provide a full suite of insurance, co-pay and patient-assistance-services for all patients where allowed by state law. The switch will take place August 1.

It is important that current and new patients enroll to the new distribution arrangement to ensure uninterrupted medicine supply. Please complete the Sucraid® enrollment form and fax to 1-866-777-7097 or e-mail to the contacts on the form.